Betterlife Pharma Inc Stock Price, News & Analysis

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) has received a favorable written response from the FDA regarding its pre-IND application for BETR-001, a non-hallucinogenic derivative of LSD aimed at treating major depressive disorder (MDD). The FDA's guidance supports BetterLife's program for BETR-001, enabling IND-enabling toxicology studies and clinical trial preparations. The Company plans to initiate human clinical trials for BETR-001 in the U.S. by Q3 2022, emphasizing its unique therapeutic potential for psychiatric disorders.

BetterLife Pharma reported positive results from an oral bioavailability and food-effect pharmacokinetic study on BETR-001 (2-bromo-LSD) in beagle dogs. Key findings include:

• Oral bioavailability of BETR-001 was around 61% for fasted and 63% for fed states.
• No significant difference in bioavailability based on feeding status.
• The drug reached peak concentration at 0.5 hours and remained detectable for up to 8 hours.

These results support the therapeutic potential of BETR-001 and bolster plans for filing its IND application with the FDA, aiming to initiate human trials in H2 2022.

BetterLife Pharma Inc. announced the appointment of Dr. Eleanor Fish to the Order of Canada for her significant contributions to immunology. Dr. Fish, a member of BetterLife’s Advisory Board, has made pivotal advancements in using interferon-alpha for disease treatment. This honor highlights her role as a Principal Investigator in a Phase 2 clinical trial for inhaled interferon-alpha2b against COVID-19 at Pontificia Universidad Católica de Chile. The Company expresses pride in Dr. Fish's achievements as it continues its commitment to developing treatments for mental disorders.

BetterLife Pharma Inc. announced a non-brokered financing of up to US$5.0 million through its subsidiary, Altum Pharmaceuticals Inc., with an investor group. The financing will be conducted in tranches starting January 2022. Once completed, the investor group will own approximately 12.5% of Altum's shares. CEO Dr. Ahmad Doroudian highlighted the funding's importance for advancing Altum's pre-clinical and clinical programs aimed at COVID-19 treatments. Additionally, a special committee is exploring strategic options, including a potential spin-off and listing of Altum on a national exchange in the U.S.

BetterLife Pharma Inc. announced positive results for its lead compound, TD-0148A, indicating anti-depressant properties in animal models. This innovative LSD derivative aims to treat major depressive disorder (MDD) without psychedelic effects. The study demonstrated significant behavioral improvements in chronically stressed female mice. BetterLife is advancing TD-0148A towards U.S. IND application, addressing the urgent need for new antidepressants amid rising resistance to current treatments. The global market for depression drugs is projected to reach nearly $25 billion by 2030.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced that Dr. Ahmad Doroudian will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. The conference focuses on the theme "Positioning for the Psychedelic Comeback in Mental Healthcare and Beyond" and will feature discussions from key industry leaders. BetterLife is developing two compounds: TD-0148A, a non-hallucinogenic LSD derivative targeting mental disorders, and TD-010 for anxiety-related issues. The global markets for depression and benzodiazepines represent significant growth opportunities for the company.

BetterLife Pharma announced the successful completion of Phase 1 in its IN2COVID trial for inhaled interferon alpha-2b product, AP-003, aimed at treating COVID-19. Eighteen healthy subjects were enrolled, showing excellent safety and tolerability with no serious adverse events. Moving to Phase 2, the study's goal is to assess the effectiveness of AP-003 against COVID-19, especially with the emergence of variants like Omicron. The promising results from earlier studies underscore AP-003's potential as a broad-spectrum antiviral agent.

BetterLife Pharma announced the successful acquisition of behavioral animal pharmacology data for its lead compound, 2-bromo-LSD (TD-0148A), in collaboration with UC San Diego. This second-generation LSD derivative aims to treat mental disorders without psychedelic effects. The initial studies show that TD-0148A does not induce hallucinogenic responses in mice, unlike traditional LSD. BetterLife plans to advance TD-0148A towards clinical trials, focusing on treating conditions like depression and PTSD. The collaboration leverages the expertise of Dr. Halberstadt in psychedelic pharmacology.